Known targets — ChEMBL curated mechanism
ACVR1ADORA1ADORA2AADORA2BADORA3ESR1ESR2FLT3GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSC1HRH1HTR7IDH1IDH2IRAK1JAK1JAK2JAK3MEN1OPRM1P2RX3PDE5ASCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASIGMAR1SLC6A2SYKTACR1TOP2ATYK2
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.94 |
| ▸ | HMGCR | P04035 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | ACLY | P53396 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | SLC13A5 | Q86YT5 | 4/20 | 0.42 |
| ▸ | CPT2 | P23786 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL9361094 | 1.00 | ALDH1A1 (0.94) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL29486777 | 1.00 | ALDH1A1 (0.94) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL29369759 | 0.97 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL5269305 | 0.97 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL240402 | 0.97 | ALDH1A1 (1.00) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL1331942 | 0.97 | ALDH1A1 (1.00) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL3417188 | 0.97 | ALDH1A1 (1.00) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL10896997 | 0.97 | ALDH1A1 (1.00) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL842 | 0.97 | ALDH1A1 (1.00) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL725546 | 0.97 | ALDH1A1 (1.00) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2595635-A1 | POLYDEOXYRIBONUCLEOTIDES (PDRNS) FOR USE IN THE TREATMENT OF METABOLIC AND/OR LACTIC ACIDOSIS AND POLYDEOXYRIBONUCLEOTIDE-BASED COMPOSITIONS FOR THE AFORESAID USE | Medestea Internazionale S.p.A. (IT) | 2013-05-29 | — | — | EP | claimed |
| US-20130122091-A1 | POLYDEOXYRIBONUCLEOTIDE-BASED COMPOSITIONS AND THEIR METHODS OF USE | MEDESTEA INTERNAZIONALE SPA (IT) | 2013-05-16 | — | — | US | claimed |
| WO-2012011063-A1 | POLYDEOXYRIBONUCLEOTIDES (PDRNS) FOR USE IN THE TREATMENT OF METABOLIC AND/OR LACTIC ACIDOSIS AND POLYDEOXYRIBONUCLEOTIDE-BASED COMPOSITIONS FOR THE AFORESAID USE | MEDESTEA INTERNAZIONALE S.P.A. (IT) | 2012-01-26 | — | — | WO | claimed |
| US-20040224076-A1 | Dietetic composition in the form of a salt substitute for table salt | SANOFI-AVENTIS (FR) | 2004-11-11 | — | — | US | claimed |
| EP-1051086-B1 | DIETETIC COMPOSITION IN THE FORM OF A SUBSTITUTION SALT FOR TABLE SALT | SANOFI SYNTHELABO (FR) | 2002-04-17 | — | — | EP | claimed |
| EP-2595635-A1 | POLYDEOXYRIBONUCLEOTIDES (PDRNS) FOR USE IN THE TREATMENT OF METABOLIC AND/OR LACTIC ACIDOSIS AND POLYDEOXYRIBONUCLEOTIDE-BASED COMPOSITIONS FOR THE AFORESAID USE | Medestea Internazionale S.p.A. (IT) | 2013-05-29 | — | — | EP | disclosed |
| US-20130122091-A1 | POLYDEOXYRIBONUCLEOTIDE-BASED COMPOSITIONS AND THEIR METHODS OF USE | MEDESTEA INTERNAZIONALE SPA (IT) | 2013-05-16 | — | — | US | disclosed |
| WO-2012011063-A1 | POLYDEOXYRIBONUCLEOTIDES (PDRNS) FOR USE IN THE TREATMENT OF METABOLIC AND/OR LACTIC ACIDOSIS AND POLYDEOXYRIBONUCLEOTIDE-BASED COMPOSITIONS FOR THE AFORESAID USE | MEDESTEA INTERNAZIONALE S.P.A. (IT) | 2012-01-26 | — | — | WO | disclosed |
| US-20040224076-A1 | Dietetic composition in the form of a salt substitute for table salt | SANOFI-AVENTIS (FR) | 2004-11-11 | — | — | US | disclosed |
| US-4867942-A | Process for the preparation of an effervescent granular material, effervescent granular material prepared by this process, as well as the use thereof | GERGELY GERHARD (AT) | 1989-09-19 | — | — | US | disclosed |
| EP-0298085-A1 | ULTRADENSE AND MORE SOLUBLE AND BIOAVAILABLE PREPARATIONS OF CALCIUM CITRATE. | UNIV TEXAS (US) | 1989-01-11 | — | — | EP | disclosed |
| WO-1987005507-A1 | ULTRADENSE AND MORE SOLUBLE AND BIOAVAILABLE PREPARATIONS OF CALCIUM CITRATE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1987-09-24 | — | — | WO | disclosed |